Setogepram

Setogepram (PBI-4050, Fezagepras) is an experimental drug which acts as a mixed agonist-antagonist for certain free fatty acid receptors, being an agonist at FFAR1 (GPR40) but an antagonist at GPR84. It has antiinflammatory and anti-fibrotic effects and has reached Phase II human clinical trials for treatment of idiopathic pulmonary fibrosis.^{[1][2][3][4][5]}

Other namesPBI-4050, Fezagepras

CAS Number

• 1002101-19-0

PubChem CID

• 24749700

IUPHAR/BPS

• 10043

Quick facts Clinical data, Other names ...

Setogepram

Clinical data
Other names	PBI-4050, Fezagepras
Identifiers
IUPAC name 2-(3-pentylphenyl)acetic acid
CAS Number	1002101-19-0
PubChem CID	24749700
IUPHAR/BPS	10043
DrugBank	DB15447
ChemSpider	58107628
UNII	879OVM0Y1S
ChEMBL	ChEMBL4297635
Chemical and physical data
Formula	C13H18O2
Molar mass	206.285 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCCCC1=CC(=CC=C1)CC(=O)O
InChI InChI=1S/C13H18O2/c1-2-3-4-6-11-7-5-8-12(9-11)10-13(14)15/h5,7-9H,2-4,6,10H2,1H3,(H,14,15) Key:PEGQOIGYZLJMIB-UHFFFAOYSA-N

Close